Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier

Clinical Cancer Research

Volumn 18, Issue 14, 2012, Pages 3952-3960

  Kerr, Sarah E ^a   Schnabel, Catherine A ^b   Sullivan, Peggy S ^c   Zhang, Yi ^b   Singh, Veena ^b   Carey, Brittany ^d   Erlander, Mark G ^b   Highsmith, W Edward ^a   Dry, Sarah M ^c   Brachtel, Elena F ^d  

^a MAYO CLINIC   (United States)

^b BioTheranostics Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CLASSIFIER; CONTROLLED STUDY; FEMALE; GENE MOLECULAR CANCER CLASSIFIER; HUMAN; HUMAN TISSUE; MALE; METASTASIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR CLASSIFICATION;

ADULT; AGED; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAFFIN EMBEDDING; PROGNOSIS; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863911666     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0920     Document Type: Article

References (52)

1. American Cancer Society. Cancer facts & figures 2010. Atlanta, GA: American Cancer Society; 2010 [cited 2010 September 29]. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-026238.pdf.
2. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al., editors. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; 2010. Available from: http://seer.cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site.
3. Greco FA, Hainsworth JD. Cancer of unknown primary site. In:DeVita VTJ, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011. p. 2033-51.
4. Hillen HF. Unknown primary tumours. Postgrad Med J 2000;76:690-3.
5. Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A. Targeted therapies: how personal should we go? Nat Rev Clin Oncol 2012;9:87-97.
6. La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 2011;8:587-96.
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
8. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 3534).
9. Varadhachary GR. Carcinoma of unknown primary: focused evaluation. J Natl Compr Canc Netw 2011;9:1406-12.
10. Anderson GG, Weiss LM. Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance. Appl Immunohistochem Mol Morphol 2010;18:3-8.
11. Levi F, Te VC, Erler G, Randimbison L, La Vecchia C. Epidemiology of unknown primary tumours. Eur J Cancer 2002;38:1810-2.
12. DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Semin Diagn Pathol 2000;17:184-93. (Pubitemid 30641873)
13. Glover KY, Varadhachary GR, Lenzi R, Raber MN, Abbruzzese JL. Carcinoma of unknown primary. Clinical oncology. 4th ed. Philadelphia, PA; Churchill Livingstone; 2008. p. 2057-74.
14. Tong KB, Murtagh KN, Hubert H, Santry B, Lenzi R, Hess KR, et al. Patient survival and health care utilization in Medicare beneficiaries diagnosed with cancer of unknown primary. J Clin Oncol 2006;24:6064.
15. Schapira DV, Jarrett AR. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med 1995;155:2050-4.
16. Hamilton CS, Langlands AO. ACUPS (adenocarcinoma of unknown primary site): a clinical and cost benefit analysis. Int J Radiat Oncol Biol Phys 1987;13:1497-503. (Pubitemid 17164171)
17. Pavlidis N, Merrouche Y. The importance of identifying CUP subsets. In:Fizazi K, editor. Carcinoma of unknown primary site. New York, NY: Taylor & Francis Group; 2006. p. 37-48.
18. Bugat R, Bataillard A, Lesimple T, Voigt JJ, Culine S, Lortholary A, et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 2003;89 Suppl 1:S59-66. (Pubitemid 37076150)
19. Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 2008;9:596-9. (Pubitemid 351722584)
20. Hainsworth JD, Schnabel CA, Erlander MG, HainesDWIII, Greco FA. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer 2012;11:112-8.
21. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008;26:462-9. (Pubitemid 351501813)
22. Ma XJ, Patel R, Wang X, Salunga R, Murage J, Desai R, et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 2006;130:465-73.
23. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008;26:4442-8.
24. Monzon FA, Lyons-Weiler M, Buturovic LJ, Rigl CT, Henner WD, Sciulli C, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 2009;27:2503-8.
25. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 2001;98:15149-54. (Pubitemid 34013984)
26. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001;61:7388-93. (Pubitemid 32995021)
27. Bloom G, Yang IV, Boulware D, Kwong KY, Coppola D, Eschrich S, et al. Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol 2004;164:9-16. (Pubitemid 38364584)
28. Tothill RW, Kowalczyk A, Rischin D, Bousioutas A, Haviv I, van Laar RK, et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005;65:4031-40. (Pubitemid 40775639)
29. Erlander MG, Ma XJ, Kesty NC, Bao L, Salunga R, Schnabel CA. Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn 2011;13:493-503.
30. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003;56:1129-35. (Pubitemid 37386338)
31. Pillai R, Deeter R, Rigl CT, Nystrom JS, Miller MH, Buturovic L, et al. Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn 2011;13:48-56.
32. Rosenwald S, Gilad S, Benjamin S, Lebanony D, Dromi N, Faerman A, et al. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol 2010;23:814-23.
33. Raab SS, Grzybicki DM, Janosky JE, Zarbo RJ, Meier FA, Jensen C, et al. Clinical impact and frequency of anatomic pathology errors in cancer diagnoses. Cancer 2005;104:2205-13. (Pubitemid 41579968)
34. Stang A, Pohlabeln H, Muller KM, Jahn I, Giersiepen K, Jockel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer 2006;52:29-36. (Pubitemid 43340196)
35. Stancel GA, Coffey D, Alvarez K, Halks-Miller M, Lal A, Mody D, et al. Identification of tissue of origin in body fluid specimens using a gene expression microarray assay. Cancer Cytopathol 2012;120:62-70.
36. Moraleda J, Grove N, Tran Q, Doan J, Hull J, Nguyen L, et al. Gene expression data analytics with interlaboratory validation for identifying anatomical sites of origin of metastatic carcinomas. J Clin Oncol 2004;22:9625.
37. Schroeder BE, Laouri M, Chen E, Erlander MG, Schnabel CA. Pathological diagnoses in cases of indeterminate or unknown primary submitted for molecular tumor profiling [abstract]. In: Proceedings of the 101st Annual Meeting of the United States and Canadian Academy of Pathology; 2012 Mar 17-23. Vancouver, BC, Canada: Vancouver Convention Centre; 2012. Abstract nr. 429.
38. Seidman JD, Zhao P, Yemelyanova A. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 2011;120:470-3.
39. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011;42:918-31.
40. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-43.
41. Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 2010;16:2266-74.
42. Wick MR, Ockner DM, Mills SE, Ritter JH, Swanson PE. Homologous carcinomas of the breasts, skin, and salivary glands. A histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma, and salivary duct carcinoma. Am J Clin Pathol 1998;109:75-84. (Pubitemid 28023814)
43. Clauditz TS, Reiff M, Gravert L, Gnoss A, Tsourlakis MC, Munscher A, et al. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas. Pathology 2011;43:459-64.
44. Sogawa K, Watanabe M, Sato K, Segawa S, Miyabe A, Murata S, et al. Rapid identification of microorganisms by mass spectrometry: improved performance by incorporation of in-house spectral data into a commercial database. Anal Bioanal Chem 2012;403:1811-22.
45. Saffert RT, Cunningham SA, Ihde SM, Jobe KE, Mandrekar J, Patel R. Comparison of Bruker Biotyper matrix-assisted laser desorption ionization-time of flight mass spectrometer to BD Phoenix automated microbiology system for identification of gram-negative bacilli. J Clin Microbiol 2011;49:887-92.
46. Guerriere-Kovach PM, Hunt EL, Patterson JW, Glembocki DJ, English JC III, Wick MR. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes. Am J Clin Pathol 2004;122:70-7. (Pubitemid 38849874)
47. Montone KT, van Belle P, Elenitsas R, Elder DE. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 1997;10:939-44. (Pubitemid 27431970)
48. Bussolati G, Leonardo E. Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 2008;61:1184-92.
49. Leong TY, Cooper K, Leong AS. Immunohistology-past, present, and future. Adv Anat Pathol 2010;17:404-18.
50. Leong AS. Pitfalls in diagnostic immunohistology. Adv Anat Pathol 2004;11:86-93.
51. Agoff SN, Lamps LW, Philip AT, Amin MB, Schmidt RA, True LD, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 2000;13:238-42. (Pubitemid 30207508)
52. Kubba LA, McCluggage WG, Liu J, Malpica A, Euscher ED, Silva EG, et al. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol 2008;21:485-90. (Pubitemid 351441040)